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Treatment of tumor-bearing mice with mouse (m)TNF-a, targeted to tumor vasculature 
by the anti-ED-B fibronectin domain antibody L19(scFv) and combined with melphalan, 
induces a therapeutic immune response. Upon treatment, a highly efficient priming of 
CD4+ T cells and consequent activation and maturation of CD8+ CTL effectors is 
generated, as demonstrated by in vivo depletion and adoptive cell transfer experiments. 
Immunohistochemical analysis of the tumor tissue demonstrated massive infiltration of 
CD4+ and CD8+ T cells 6 days after treatment and much earlier in the anamnestic 
response to tumor challenge in cured mice. In fact, the curative treatment with 
L19mTNF-a and melphalan resulted in long-lasting antitumor immune memory, 
accompanied by a mixed Th1/Th2-type response and significant in vitro tumor-specific 
cytolytic activity. Finally, the combined treatment reduced the percentage and absolute 
number of CD4+CD25+ regulatory T cells in the tumor-draining lymph nodes of mice 
responding to therapy, and this was associated with the establishment of protective 
immunity. These findings pave the way for alternative therapeutic strategies based on 
the targeted delivery of biological and pharmacological cytotoxic compounds that not 
only kill most of the tumor cells but, more importantly, trigger an effective and longlasting 
antitumor adaptive immune response. 
 
Introduction 
Although several immunotherapeutic approaches have been successfully used in the activation and 
expansion of tumor-specific T lymphocytes in animal models [1, 2], to date their application in 
cancer patients has been rather disappointing. Many studies have highlighted the potent and 
diversified capacity of different tumors to evade antitumor immune responses, among which are the 
loss of tumor-associated surface antigens [3], the downregulation of MHC class I expression [4], the 
accumulation of inhibitory immature myeloid cells [5] and the release of inhibitory cytokines or 
immunosuppressive factors, e.g. IL-10 and TGF-b [6, 7]. More recently a distinctive T cell 
subpopulation with a CD4+CD25+ phenotype, designated regulatory T cells (Treg), has been 
described to have an important function in the regulation of peripheral tolerance and in the 
suppression of antitumor effector responses [8, 9]. Induction of antitumor cytolytic T lymphocytes 
(CTL) displaying a CD8+ phenotype is a fundamental part of the effector mechanisms against the 
tumor, as these cells are able to recognize and kill, in an MHC class I-restricted fashion, the cancer 
cells both in vitro and in vivo. However, their activation and expansion are largely dependent on the 
action of antigen-specific CD4+ T helper (Th) cells [10–12]. Thus, current approaches to cancer 
vaccination are aimed at triggering both Th and CTL tumor-specific immune responses [13, 14] and 
at eliminating inherent suppressive mechanisms that can impact these cells [15]. Activation of 
CD4+ Th cells is often accompanied by polarization into two distinct functional phenotypes, Th1 
and Th2, depending mainly on the pattern of cytokine production. It has been shown that IFN-c, a 
Th1-type cytokine, plays a central role in the regulation of cellmediated antitumor immunity [16, 
17]. However, the view that aTh1-type response is theuniquehelper activity guiding effective 
antitumor CTL priming has been challenged by several reports demonstrating that Th1/ 
Th2mixedimmuneresponses also strongly correlate with the induction of potent and effective 
antitumor CTL responses and with tumor rejection processes [18–20]. Tumor necrosis factor alpha 
(TNF-a) is a pleiotropic homotrimeric cytokine [21, 22] that exerts its major antitumor effects via a 
preferential toxicity for the endothelial cells of the tumor-associated vasculature, with extensive 
thrombosis and destruction of tumor vasculature resulting in extensive tumor necrosis, and through 
an increase in the antitumor immune response [23–25]. TNF-a increases vascular permeability [26] 
and reduces the tumor's interstitial fluid pressure [27], a process pivotal to facilitating the 
penetration of antitumor agents at the tumor site. Although TNF-a is one of the most potent 
antitumor cytokines, its unacceptable toxic side effects have prevented its systemic administration 
at therapeutically effective doses. To date, the clinical use of TNF-a has been limited to loco-
regional applications, such as “Isolated Limb Perfusion” (ILP) in combination with melphalan for 
the treatment of nonresectable high-grade sarcoma and melanoma [28, 29]. We previously 
demonstrated that the ED-B-containing fibronectin isoform (B-FN) is a marker of angiogenesis [30, 
31] and that endothelial cells invading tumor tissues migrate along extracellular matrix (ECM) 
fibers containing B-FN [32]. The possibility to selectively target tumor vasculature using a human 
recombinant antibody specific for B-FN, L19(scFv), in both experimental animal models and cancer 
patients [32–35] paved the way for the antibody's use in vivo for both diagnostic and therapeutic 
purposes. Indeed, the selective targeted delivery of cytokines to the B-FN using L19(scFv) 
dramatically enhances their anticancer properties [36–38]. We generated the fusion protein 
L19mTNF-a [38], consisting of mouse TNF-a (mTNF-a) and the human antibody fragment 
L19(scFv) directed to the B-FN. When injected intravenously (i.v.) into tumor-bearing mice, this 
fusion protein selectively accumulates around the tumor vasculature and, 48 h after injection, the 
dose of L19mTNF-a in the tumor is roughly 35 times higher than the dose achieved with a control 
fusion protein in which mTNF-a is conjugated to an irrelevant scFv. A single systemic treatment 
with L19mTNF-a and melphalan has been shown to be highly effective in two histologically 
unrelated mouse tumor models, WEHI- 164 fibrosarcoma and C51 colon carcinoma, implanted in 
syngeneic BALB/c mice [39]. Importantly, a longlasting Tcell-mediated immune response against 
tumors involving both CD4+ and CD8+ T cells is induced by the combined therapy, and this 
correlates with the capacity to reject new tumor challenges and metastases, even of different 
histological origins [39]. Here we focused our investigation on characterization of the early events 
of the antitumor immune response after combined therapy with L19mTNF-a and melphalan in order 
to understand the regulatory mechanisms and the cell subpopulations involved in the triggering and 
maintenance of the protective antitumor immunity.  
 
Results  
In vivo depletion of CD4+ or CD8+ T cells abolishes the therapeutic efficacy of L19mTNF-a 
and melphalan  
We previously showed that the treatment of tumorbearing mice with L19mTNF-a and melphalan 
cures about 80% of WEHI-164 and 30% of C51 tumor-bearing BALB/c mice and that the host's 
immune system is fundamental for treatment efficacy and induction of the specific antitumor 
memory that protects the animals from subsequent tumor challenges [39]. To study the contribution 
of distinct lymphocyte subpopulations in the early processes leading to tumor cure, groups of ten 
animals were deprived of CD4+ T cells, CD8+ T cells or NK cells by injecting specific antibodies 
intraperitoneally. Antibodies were injected at days –2, 0 and +2 from WEHI-164 tumor cell 
injection (day 0) (Fig. 1). Treatment was performed on days 6 and 7. Removal of either CD4+ or 
CD8+ T cells completely abrogated the therapeutic effects (Fig. 1A, B), thus demonstrating that 
both CD4+ and CD8+ Tcells are needed for tumor rejection. Conversely, removal of NK cells did 
not affect the efficacy of the treatment, since 80% of NK-deprived animals were cured of WEHI-
164 tumor (Fig.1C), aswere the animals treated with control rat antibodies (Fig. 1D) or rabbit serum 
(data not shown). Primed CD4+ T cells trigger naive CD8+ T cells into antitumor effectors in vivo 
In light of the results of the in vivo cell depletion experiments described above (Fig. 1), additional 
experiments were carried out to better evaluate the relevance of the host's CD4+ and CD8+ T cells 
in the triggering of the antitumor effector functions. Naive animals were in vivo-deprived of either 
CD4+ or CD8+ T cells by i.p. injections of specific antibodies at days –2, 0, and +2. At day 0 
WEHI-164 tumor cells were coinjected s.c. with either CD4- or CD8-depleted immune spleen cells. 
We then compared the in vivo protection from WEHI- 164 tumor growth exerted by CD4-depleted 
immune spleen cells in immunocompetent or CD4-deprived mice and the protection by CD8-
depleted immune spleen cells in immunocompetent or CD8-deprived mice. Using CD4-depleted 
immune splenocytes, no survival differences were observed between the immunocompetent and the 
in vivo CD4-depleted mice (Fig. 2A); indeed, 20% of tumor-free mice (1/5), were found in both 
groups 2 months after cell transfer. In contrast, dramatic differences were found using CD8-
depleted immune splenocytes, since these cells were able to protect 80% (4/5) of immunocompetent 
mice and 0% (0/5) of in vivo CD8-depleted mice (Fig. 2B). These results indicate that CD4+ T cells 
cannot be regarded as effectors per se but rather as classical helper cells necessary to trigger naive 
CD8+ T cells in the host for effector functions. To confirm this helper role of primed antitumor 
CD4+ T cells for both unprimed and primed CD8+ T cells, the Winn assay was performed in 
immunodeficient SCIDbg mice (Fig. 2C). While total immune splenocytes from tumor-cured 
donors were able to protect 80% (4/5) of SCIDbg mice from WEHI-164 tumor growth, no 
protection was achieved with immune spleen cells depleted of CD4+ T cells in vitro. Similarly, 
injection of in vitro-depleted antitumor CD8+ effector T cells in this system also resulted in a lack 
of protection from tumor growth.  
 
Tumor tissue correlates of immunity in the priming and memory phases  
The phenotype of tumor-infiltrating leukocytes was evaluated on WEHI-164 tumor cryostat 
sections at different times after tumor cell injection in naive mice (Fig. 3A) and in mice that had 
previously rejected a first tumor injection (Fig. 3B, cured mice). In the priming phase (Fig. 3A), 
CD4+ T cells were observed already at day 6 after tumor cell inoculation, just before treatment. By 
contrast, CD8+ Tcell infiltration was barely visible at this time. A remarkable increase in the 
number of CD4+ and CD8+ T cells infiltrating the tumor was seen at day 12 after tumor cell 
injection in treated animals (day 6 after treatment) as compared to untreated animals. A similar 
behavior was observed for B cells (B). In contrast, macrophage (Mu) and NK cell (NK) infiltration, 
particularly prominent at day 7 after tumor cell injection, showed no appreciable differences 
between treated and untreated animals at most time points analyzed, with the possible exception of 
macrophages on day 9. In untreated animals, granulocyte infiltration (Gr) was low at all time points 
analyzed. In contrast, a massive and dramatic granulocyte infiltration was observed already 24 h 
after the first treatment (day 7 after tumor cell inoculation). This correlated with a rapid induction of 
tumor necrosis by L19mTNF-a, as previously observed [38]. Granulocyte infiltration diminished in 
the following days to increase again dramatically at day 12 after tumor cell inoculation, the time at 
which the rapid and dramatic increase in CD4+ and CD8+ T lymphocytes was also observed. The 
characteristics of the tumor cellular infiltrate were then analyzed in mice that had been cured of 
WEHI-164 tumor following combined treatment and that were further challenged with a 
tumorigenic dose of 3  106 homologous tumor cells (cured mice, Fig. 3B). Comparison was 
carried out with tumor tissues taken 4 and 6 days after tumor cell injection in control naive animals. 
CD4+ and CD8+ T cells rapidly and massively infiltrated tumor tissues of rejecting mice, and their 
numbers increased from day 4 to day 6 after tumor cell inoculation. A similar behavior was 
observed for B cells (B), although in this case the number of infiltrating cells was higher at day 4 as 
compared to day 6. Macrophage infiltration (Mu) was also increased in tumor-rejecting mice with 
respect to control animals at the two time points analyzed. NK cell infiltration (NK) was strongly 
increased in rejecting mice, but only at day 4, while granulocyte infiltration (Gr) was strongly and 
statistically significantly increased only at day 6. 
 
 L19mTNF-a and melphalan induce a persistent mixed Th1/Th2 polarization  
To study in more detail the initial triggering of the antitumor immune response, particularly the 
early events of T cell priming, we investigated the frequency, phenotype and functional importance 
of the CD4+ Tcell subpopulations (Th1 and Th2) in WEHI-164 tumorbearing mice before and soon 
after therapy with L19mTNF-a and melphalan. The results of ELISPOT assays measuring the 
frequency of ex vivo spleen cells producing IFN-c or IL-4 (Fig. 4A, B) in response to in vitro 
stimulation with the same (WEHI-164) or a different (C51) tumor cell line, showed that in untreated 
WEHI-164 tumor-bearing mice (UT), the number of spleen cells secreting IL-4 in response to both 
homologous and heterologous tumors was high, while IFN-c-producing cells were almost 
undetectable. A similar pattern of the Th2-type response was found in tumor-bearing mice treated 
with melphalan alone. In contrast, as compared to untreated tumor-bearing mice, treatment with 
L19mTNF-a alone induced high frequencies of IFN-c-producing spleen cells and a remarkable 
reduction in IL-4-producing spleen cells in response to both tumor cells. When melphalan was 
given in combination with L19mTNF-a, a mixed Th1/Th2-type response, with high numbers of 
both IFN-c- and IL-4- secreting spleen cells, again to both tumor cell lines, was observed (Fig. 4A 
and B).Moreover, the mixed Th1/Th2 response was still very strong after 1 month and persisted, 
albeit at lower frequencies, at least up to 5 months after WEHI-164 tumor cure (Fig. 4A, B). At this 
time, a new WEHI-164 tumor challenge strongly increased the frequency of spleen cells displaying 
a Th1/ Th2-type response to both WEHI-164 and C51 tumor cells (anamnestic immune response; 
Fig. 4A, B) 2 wk after challenge. Importantly, both IFN-c- and IL-4- secreting spleen cells 
responding to tumor challenge were mostly of the CD4-positive phenotype, and their function was 
blocked by pre-treatment of the cells with anti-MHC class II antibodies but not anti-MHC class I 
antibodies (Fig. 4A, B, right panels) To evaluate the in vivo role of IFN-c produced by Th1 cells, 
IFN-c–/– mice bearing WEHI-164 tumors were treated with L19mTNF-a and melphalan. As shown 
in Fig. 4C, no tumor cure was achieved in this group of mice (0/5), underlining the key role exerted 
by this cytokine in the early events of the protective antitumor response generated after treatment. 
 
 A down-modulation of CD4+CD25+ Treg is induced by therapy 
In order to evaluate the involvement of CD4+CD25+ Treg in the process of tumor growth and in the 
antitumor immune response induced by L19mTNF-a/melphalan treatment, both the quantitative 
variations and the function of this Tcell subset in the draining lymph nodes of WEHI-164 tumor-
bearing mice were analyzed after various modalities of treatment. Table 1 summarizes the 
quantitative results. In naive BALB/c mice, CD4+CD25+ Treg cells represented about 6% of the 
lymph node cells. This value rose to more than 11% in untreated mice bearing growing WEHI-164 
2 wk after tumor cell injection and dropped to 4.6% in those mice undergoing the various 
therapeutic protocols resulting in reduction of tumor growth at the same time point. In contrast, in 
mice with WEHI-164 tumor growth despite therapy (non-responders, NR), a much higher 
percentage of CD4+CD25+ Treg was observed (mean 7.2%). Noteworthy is that in two mice killed 
1 month after WEHI-164 tumor cure with L19mTNF-a and melphalan, CD4+CD25+ Treg still 
represented only 3.4% of the total cells in the lymph nodes. The percentage of CD25+ and FoxP3+ 
(an additional marker of Treg) double-positive cells closely paralleled the percentage of 
CD4+CD25+ cells. The total cell number in the lymph nodes of untreated mice with growing 
tumors (compared to naive mice) was reduced by about 30%, and a 20–53% reduction was 
observed after the different treatments (Table 1), returning to the level of naive mice 1 month after 
cure. The absolute number of CD4+CD25+ Treg cells in untreated tumor-bearing mice was 30% 
higher than in naive mice, while it was reduced by more than 50% after all the treatments, with the 
exception of nonresponding mice. Very similar results were obtained in C51 tumor-bearing mice 
undergoing the same therapeutic treatments (data not shown). To study and compare the function of 
CD4+CD25+ Treg of cured mice with that of untreated tumor-bearing mice, their capacity to inhibit 
responder T cell proliferation in vitro in a unidirectional mixed lymphocyte reaction (MLR) was 
assessed. The results showed that addition of increasing numbers of Treg (up to half the number of 
responder CD4+CD25– T cells) from either untreated tumor-bearing mice or from cured mice 2 wk 
after tumor cell inoculation displayed similar inhibitory capacity on syngeneic T cells proliferating 
in the MLR (Fig. 5A). The functional capacity of Treg in vivo was also evaluated by transferring 
the cells intoWEHI-164 tumorbearing animals 2 days after L19mTNF-a/melphalan treatment. As 
shown in Fig. 5B, Treg substantially counteracted the antitumor protective immunity generated by 
the therapy. Indeed, only 50% of animals injected with Treg displayed tumor cure after therapy in 
contrast to a cure rate of 80% achieved in animals not receiving Treg. Thus, the quantitative 
reduction of Treg but not their intrinsic function is an important event generated by the 
establishment of protective immunity after L19mTNF-a and melphalan treatment.  
 
Rejection of tumor challenges correlates with therapy-induced long-lasting memory CTL  
In order to characterize in detail the antitumor cytolytic T cell function generated after L19mTNF-
a/melphalan treatment of WEHI-164 tumor-bearing mice, the ability of the immune spleen cells to 
kill different tumor cell lines in a standard in vitro 4-h 51Chromium release assay was evaluated. 
Already 1 month after cure, high CTL responses specific for WEHI-164 and the heterologous C51 
tumor cells were detected (not shown). The specific lytic ability remained high 2 months after 
tumor cure (Fig. 6A) and gradually declined but was still significant after 5 months (Fig. 6B). Re-
challenge of cured mice with a tumorigenic dose of homologous cells 5 months after cure resulted 
in boosting of CTL activity against both homologous (WEHI-164) and heterologous (C51) tumor 
cells, which was MHC class I-restricted as shown by strong inhibition of lysis in presence of anti-
MHC class I mAb (Fig. 6C) but not anti-MHC class II mAb (data not shown). This activity was 
associated with fast and complete tumor rejection in vivo and was still present 10 months after 
WEHI-164 tumor cure, as 4/4 cured mice were able to reject WEHI-164 tumor, thus demonstrating 
a very long-lasting antitumor immune memory (Fig. 6D). No CTL activity was found in spleen cells 
from mice bearing growing WEHI-164 tumors or in naive mice (data not shown).  
 
Discussion  
The therapeutic combination of L19mTNF-a and melphalan induces potent stimulation of the host 
immune response that can endow the host with antitumor immunity even against heterologous 
tumors of distinct histological origin [39]. The cellular basis of this therapy-induced antitumor 
vaccination entails the strong priming of the CD4+ T cell compartment, an absolutely necessary 
prerequisite for subsequent triggering of the activation and maturation of the major antitumor 
effector mechanism represented by CD8+ CTL. The above conclusions are based on results from in 
vivo cell-depletion experiments, which have clearly demonstrated that elimination of CD4+ T cells 
from naive BALB/c mice makes the animals incapable of rejecting primary tumors after L19mTNF-
a/melphalan treatment. In vivo depletion of CD8+ T cells but not NK cells produces the same effect 
(Fig. 1). We previously demonstrated that total immune splenocytes derived from WEHI-164 
tumor-cured mice and injected into naive animals protect 100% of the mice from WEHI-164 tumor 
growth. The protection against tumor growth dropped to 25% when the immune splenocytes were 
in vitro-depleted of the CD4+ T cells before cell transfer but remained 75% after depletion of CD8+ 
T cells [39]. These results suggested that primed CD4+ Tcells are more effective than primed CD8+ 
Tcells in inducing rejection of the tumor when injected into immunocompetent unprimed animals. 
In the present study, we investigated this aspect in more detail. We found that adoptive transfer of 
CD8-depleted T cells derived from animals cured of the tumor after treatment with L19mTNF-
a/melphalan were incapable of inducing tumor rejection when injected into CD8-depleted naive 
animals (Fig. 2B), strongly suggesting that the major protective role of primed antitumor CD4+ T 
cells lies in triggering CD8+ naive T cells to become functionally mature antitumor CTL effectors. 
Moreover, adoptive transfer experiments in immunodeficient SCIDbg mice underlined the 
important role of primed CD4+ T cells in stimulating and maintaining optimal effector function of 
primed CD8+ Tcells in vivo. Taken together these results demonstrate the key role of CD4+ Tcells 
in orchestrating adaptive antitumor immunity in our experimental model of tumor therapy by 
L19mTNF-a/melphalan treatment. Immunohistochemical analysis (Fig. 3A) demonstrated dramatic 
infiltration of the tumor early after treatment, first by CD4+ Tcells and then by CD8+ Tcells. 
Impressive also was the de novo infiltration of granulocytes immediately after the tumor necrosis 
generated by the treatment and later, at the time of the greater infiltration of CD4+ T cells. The 
kinetics of CD4+ and CD8+ T cell infiltration at the tumor site was even accelerated in cured mice 
rejecting a tumor challenge (Fig. 3B) and, again, this infiltration was accompanied by a similar 
infiltration of granulocytes and macrophages. B cells were also largely present in the tumor 
infiltrate both after tumor treatment and in cured mice after tumor challenge, following kinetics 
similar to that of CD8+ Tcells. While we cannot rule out involvement of B cells in the antitumor 
response, it is no doubt marginal compared to the role played by CD4+ and CD8+ T cells. Thus, the 
major lymphocyte populations involved in the antitumor priming and tumor rejection in vivo were 
indeed also themajor populations observed in the tumor tissue of those animals undergoing 
therapeutic treatment with L19mTNF-a and melphalan aswell as in cured mice rejecting tumor 
challenge. These results strongly suggest that the massive necrosis induced by L19mTNF-
a/melphalan and the earlier infiltration of granulocytes contributing to tumor cell killing and 
digestion may play a critical role in fueling professional antigen-presenting cells (APC), such as 
dendritic cells and macrophages, with large amounts of tumor-associated antigens. By this 
reasoning, APC can then stimulate specific antitumor CD4+ Th cells and CD8+ effector CTL, 
leading to the establishment of a critical reservoir of memory effector cells responsible for the 
accelerated rejection of the tumor upon challenge. Further phenotypic and functional 
characterization of the CD4+ T cells involved in the priming of the antitumor immune response 
following treatment with L19mTNF-a/melphalan revealed that both MHC class IIrestricted Th1-
type and Th2-type cells were triggered (Fig. 4A, B). Interestingly, while melphalan preferentially 
triggered IL-4-secreting Th2-type cells, L19mTNF-a triggered exclusively CD4+ T cells secreting 
IFN-c. This Th1-derived cytokine was indeed instrumental in the process of priming and maturation 
of the immune effector functions, since IFN-c–/– knockout mice were no longer curable by the 
combined therapeutic treatment and were, thus, unable to reject the tumor (Fig. 4C). Nevertheless, 
treatment with either melphalan or L19mTNF-a alone was insufficient to generate efficient priming 
of the antitumor immune response [38, 39]. Taken together these results emphasize the role of both 
Th1 and Th2 cells in the process leading to an efficient in vivo antitumor response in our 
experimental setting. Although in some tumor systems a polarized Th2 response promotes rather 
than inhibits tumor growth and spread [40] and is associated to lack of protective antitumor immune 
response [41], in other tumor models a mixed Th1/Th2 immune response correlates with the tumor 
rejection [18–20]. Indeed, in antitumor vaccination approaches, Schuler et al. [19] showed that IL-4, 
the prototype cytokine of Th2 polarization, is pivotal in the early priming processes that lead to 
protective antitumor CTL responses. Future studies using IL-4-knockout mice will clarify this 
aspect in our experimental model. Our results suggest, however, that Th2 cells and their secreted 
cytokines may play an important role in both the recruitment of inflammatory cells of the innate 
immunity such as neutrophils to the tumor site as well as in their activation [42], which may 
contribute to the optimal activation of APC by providing excess amounts of tumor-associated 
antigens after digestion of necrotic tumor tissue. Thus, the rather abused notion that a polarized in 
vivo Th1 response is synonymous with a protective antitumor immune response, whereas a 
polarized Th2 response may even favor tumor growth, warrants seriously rethinking. The very 
efficient CD4+ T cell priming promoted by combined L19mTNF-a/melphalan treatment, an 
instrumental step for the activation and maturation of antitumor CD8+ effector CTL, resulted in the 
acquisition of long-lasting specific immune memory, since cured mice still displayed a potent 
anamnestic rejection response 10 months after treatment (Fig. 5D). The tumor-specific cytotoxic T 
effector activity (Fig. 5A–C) was present at a high level soon after therapy, decreased over the next 
5 months, and rebounded after an in vivo homologous tumor challenge, showing a strong 
correlation with the in vivo rejection capacity. This finding strongly suggests that our therapy-
induced antitumor vaccination generated a stable and protective antitumor immune reservoir from 
which CD4+ memory T cells could easily be rescued, act both on primed and unprimed CD8+ 
Tcells (favoring the rapid manifestation of effector function of the first and the maturation toward 
effector cells of the second) and finally counteract tumor take-up and growth upon challenge. This 
also indicates that the therapy-induced antitumor vaccination efficiently counteracted possible 
events of immune polarization toward a favorable pro-tumor environment. This interpretation is 
also supported by the results of characterization of CD4+CD25+ Treg in tumor-bearing mice, 
untreated and treated with L19mTNF-a and melphalan. It is widely accepted that Treg are involved 
in the control of activation and effectiveness of T cell immune responses and in the immune 
tolerance to tumors [8, 9, 40, 43, 44]. Moreover, and relevant for our studies, the number of 
peripheral blood Treg is increased in rheumatoid arthritis patients treated with anti-TNF-a [45], 
whereas in tumor-bearing hosts the number and function of Treg are down-regulated by low doses 
of the alkylating drug cyclophosphamide, resulting in potentiation of the antitumor immune 
responses [46]. Here we show that tumor-bearing mice treated with L19TNF-a and the alkylating 
drug melphalan, both alone and in combination, showed a significant reduction of Treg in their 
draining lymph nodes as compared to either untreated or naive mice (Table 1). This 
downmodulation was induced in both WEHI-164 and C51 tumor-bearing mice, was consistent with 
the FoxP3 expression (Table 1) and persisted at least 1 month after tumor cure. Moreover, those 
mice not responding to combined therapy with tumor volume reduction (nonresponding mice) 
presented significantly higher levels of Treg compared to responding mice. In vitro and in vivo 
functional studies further suggested that the quantitative reduction of Treg but not their intrinsic 
function was associated with the establishment of protective antitumor immunity. In fact, Treg from 
untreated tumorbearing mice and cured mice were equally efficient in inhibiting T cell proliferation 
of syngeneic cells in MLR, and Treg from untreated tumor-bearing mice could inhibit the 
therapeutic effect of L19mTNF-a and melphalan in vivo. Because all the reported treatments 
reduced Treg to a similar extent, it is possible that the establishment of protective immunity 
generated by treatment with L19mTNF-a and melphalan also acts via the quantitative, but not the 
qualitative, reduction of Treg. Thus, down-modulation of CD4+CD25+ Treg, although insufficient 
per se in inducing a protective antitumor response, may nevertheless participate in the complex 
series of cellular and molecular events that generate a stable and polarized antitumor immune 
response in our model. In conclusion, these findings demonstrate that the targeted delivery of 
L19mTNF-a in conjunction with melphalan not only results in killing of most of the tumor cells but, 
more importantly, triggers an effective and long-lasting antitumor adaptive immune response.  
 
Materials and methods 
Animal tumor models 
WEHI-164 mouse fibrosarcoma (ECACC, Sigma Aldrich, Milan, Italy) and C51 mouse colon 
adenocarcinoma (kindly provided by Dr. M. P. Colombo, Department of Experimental Oncology, 
Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy), both of BALB/c origin,were 
cultured in D-MEM medium supplemented with L-glutamine and 10% fetal bovine serum (FCS) in 
a 5% CO2 atmosphere at 37C. WEHI-164 (3  106) and C51 (25  104) cells were 
subcutaneously (s.c.) implanted in the left flank of 8- to 10- week-old immunocompetent syngeneic 
BALB/c mice or severely immunocompromised beige (SCIDbg) mice (Harlan UK, Oxon, UK). 
IFN-c–/– (BALB/c) mice [47] were purchased from The Jackson Laboratory (Bar Harbor, ME). 
The tumor volume was determined using the following formula: (d)2  D  0.52, where d and D 
are the short and long dimension (cm) of the tumor, respectively, measured with a caliper. Mice 
were killed when the tumor reached a volume of 1.5 cm3. Housing, treatment and sacrifice of 
animals followed national legislative provisions (Italian law no. 116 of 27 January, 1992).  
 
Tumor therapy  
Groups of tumor-bearing mice (*0.2 cm3 tumor volume) received an injection in their tail vein of 
100 lL phosphatebuffered saline (PBS; 20 mMNaH2PO4, 150 mMNaCl, pH 7.4) containing the 
fusion protein L19mTNF-a (0.7 pmol/g in the combined treatments; 1 pmol/g as a single 
therapeutic) obtained and purified as described [38]. The control group received PBS only. 
Melphalan (Alkeran, Glaxo Smith Kline, Research Triangle Park, NC, USA), reconstituted in the 
solvent provided by the manufacturer immediately before use and further diluted in PBS, was given 
i.p. (4.5 lg/g in 400 lL) 24 h later. The weight loss was recorded daily and never exceeded 5% 
within 72 h of the treatments. The tumor growth curves were recorded and the results of the 
treatment expressed as percent of survival versus time.  
 
In vivo and in vitro cell subset depletion  
Cell subset in vivo depletions were performed as previously described [41] by i.p. injections of anti-
CD4 (GK1.5; ATTC, Rockville, MD), anti-CD8 (2.43; ATTC) rat mAb and antiasialo- GM1 (anti-
NK rabbit serum; Wako Chemicals GmbH, Dusseldorf, Germany). Control animals received normal 
rabbit serum or an irrelevant rat mAb, as described [41]. Depletion efficiency for each cellular 
subset was always >90% as assessed by immunofluorescence and FACS analysis (Becton 
Dickinson, Milan, Italy) on splenocytes of two euthanized mice derived from each group. For in 
vitro depletion, spleen cells were treated with either anti-CD8 or anti-CD4 antibodies following a 
two-step procedure, as already described [39]. Cell depletion efficiency was assessed by 
immunofluorescence and cytofluorimetric analysis by direct staining for CD4 (FITCconjugated 
YTS 191.1.2 mAb; Immunotools, GmbH, Germany) or CD8 (PE-conjugated YTS 169.4 mAb; 
Immunotools) and was always >95%.  
 
Immunohistochemical analyses  
Cryostat sections (6 lm thick) were air-dried and fixed in cold acetone for 10 min. Immunostaining 
was performed using a previously described procedure [30] and the following primary antibodies: 
anti-CD4 (GK1.5), anti-CD8 (2.43), anti-granulocyte Ly-6G (Gr-1; clone RB6–8C5), anti-
macrophage (clone MOMA-1; ImmunoKontact), anti-B (clone RA3–3A1/6.1; ATCC) and anti-NK 
(anti-asialo-GM1). Quantitative studies of stained sections were performed independently by three 
researchers in a blind fashion. Cell counting was carried out in 8–12 randomly chosen fields under a 
Leica Wetzlar light microscope (Germany) at 400 magnification, 0.180 mm2/field. The results are 
expressed as cell number per high magnification microscopic field (cell no./HMMF, mean  SE). 
Mann Whitney U-test was used to evaluate statistically significant differences between the groups.  
 
Adoptive immunity transfer experiments (Winn assay)  
WEHI-164 tumor-cured mice were s.c. boosted in the contralateral flank with the same tumor cells 
(3  106). After 12 days the mice were killed, their spleen was removed, and a spleen cell 
suspension was prepared [48]. Total or in vitrodepleted splenocytes (see section In vivo and in vitro 
Cell Subset depletion) were mixed with 3  106 WEHI-164 tumor cells (1/ 1 ratio) and co-injected 
into naive animals [39]. The results are expressed as percent of survival versus time.  
 
ELISPOT assay  
Frequencies of IFN-c- or IL-4-producing spleen cells were determined using an enzyme-linked 
immunospot (ELISPOT) assay performed with ex vivo total splenocytes or, as specified, with 
purified CD4+ and CD8+ T cells co-cultured with irradiated WEHI-164 or C51 tumor cells as 
antigen, as described [41]. Purification was carried out using an immunomagnetic procedure. 
Briefly, negative selection was performed with a pool of mAb specific for all cells except CD4- or 
CD8-positive cells (CD4+ and CD8a+ T cell isolation kit, respectively; Miltenyi Biotec GmbH, 
Bergisch Gladbach, Germany). Purity was >95%, as assessed by immunofluorescence. In the case 
of testing with purified CD4+ T cells, irradiated naive feeder spleen cells were added 1/1 to the 
effector cells. A >2-fold increase in the number of spots over the control (splenocytes cultured in 
the absence of tumor cells) was considered a positive response. In certain experiments, mAb 
specific for either MHC class I (34.1.2S clone, 50 lg/mL) or class II (K24.199 and K22.42.2 clones, 
50 lg/mL) antigens were added during the co-culture with irradiated tumor cells. Data are expressed 
as number of spot-forming cells per million spleen cells.  
 
Cell-mediated cytotoxicity assay  
The cell-mediated cytotoxicity assay was performed using splenocytes from naive, WEHI-164 
tumor-cured or WEHI-164 tumor-rejecting mice. Splenocytes were co-cultured with irradiated 
WEHI-164 cells for 5 days and then tested in a standard 4-h 51Chromium-release assay on WEHI-
164 or C51 target cells, as reported [39], in the absence or presence of anti-MHC class I (34.1.2S 
clone, 50 lg/mL) or anti-MHC class II (K24.199 and K22.42.2 clones, 50 lg/mL) antibody after 
having additionally preincubated the target cells for 30 min with either antibody. 
 
Identification of CD4+CD25+ Treg cells and assessment of their function  
The presence and the proportion of CD4+CD25+ Treg cells in tumor-draining lymph nodes were 
assessed. Cell suspensions were first incubated with anti-CD16 mAb to block Fc receptor, washed 
and stained with anti-CD4 FITC-conjugated and anti- CD25 PE-conjugated mAb (Immunotools) 
and analyzed by flow cytometry. Expression of FoxP3, an additional marker of Treg, was assessed 
in permeabilized cells using a FITC-labeled anti-FoxP3 rat mAb (clone FJK-16s; eBioscience, 
Italy). A FITClabeled rat IgG2a mAb (eBioscience) was used as a negative control. The function of 
Treg was evaluated both in vitro and in vivo. CD4+CD25– or CD4+CD25+ cell fractions were 
isolated using a two-step immunomagnetic procedure (CD4+CD25+ regulatory T cell isolation kit, 
Miltenyi Biotec) following the manufacturer's instructions. Purity was >95%, as assessed by 
immunofluorescence. For evaluation in vitro, the capacity of the Treg to inhibit syngeneic T cell 
proliferation in MLR was analyzed. Briefly, purified naive CD4+CD25– spleen cells from BALB/c 
mice were incubated with equal numbers of irradiated spleen cells from C57BL/6 mice in the 
presence of various numbers of purified Treg from tumor-draining lymph nodes of WEHI-164-
bearing mice untreated or treated with L19mTNF-a/melphalan. Proliferation was measured after 5 
days of culture and an additional 18 h pulse with 0.5 lCi/well [3H]-thymidine (Amersham 
Bioscences). For in vivo evaluation of Treg and their impact on the efficacy of L19mTNF-
a/melphalan therapy, Treg were purified from 2-wk WEHI-164 tumor-bearing mice and i.v. 
transferred (0.5  106 Treg/mouse) into treated WEHI-164 tumor-bearing mice 2 days after 
therapy. The tumor growth curves were recorded and the results of the treatment expressed as 
percent of survival versus time.   
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